Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of ACT-709478 pediatric minitablet vs adult capsule
NCT04123288Phase 1Completed
- Sponsor
- Idorsia
- Start
- Dec 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of NBI-827104 in epilepsy (2 arms), sponsored by Idorsia. Primary endpoints: Area under the plasma concentration-time curve (AUC 0-t) up to 264 hours, Area under the plasma concentration-time curve (AUC 0-inf) up to 264 hours and 3 more. Started Dec 2019; status: completed.
02
Drugs
NBI-827104
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT04123288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04123288.